Risk factor
Resilient to price shocks
Profitability factor
Excellent growth
About
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor for rheumatism; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody injection; Cipterbin, an anti-HER2 monoclonal antibody. The company is also developing products for autoimmune diseases, tumors, and other diseases. The company was founded in 2002 and is based in Shanghai, China.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,
